Accessibility Menu
Evommune logo

Evommune

(NYSE) EVMN

Current Price$11.99
Market Cap$431.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-41%
5 YearN/A
1 YearN/A
1 Month-40%

Evommune Financials at a Glance

Market Cap

$431.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$10.00M

Net Income (TTM)

-$75.99M

EPS (TTM)

-$2.39

P/E Ratio

-5.02

Dividend

$0.00

Beta (Volatility)

0.84 (Low)

Price

$11.99

Volume

325.975

Open

$12.22

Previous Close

$11.99

Daily Range

$11.94 - $12.40

52-Week Range

$11.94 - $33.20

Estimated Earnings Date

Aug 6, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evommune

Industry

Biotechnology

Employees

48

CEO

Luis C. Peña

Headquarters

Palo Alto, CA 94304, US

EVMN Financials

Key Financial Metrics (TTM)

Gross Margin

92.76%

Operating Margin

-899.92%

Net Income Margin

-759.87%

Return on Equity

-195.15%

Return on Capital

-39.05%

Return on Assets

-23.57%

Earnings Yield

-19.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$431.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.02M

Volume

325.975

Avg. Volume

721.48K

Financials (TTM)

Gross Profit

$9.28M

Operating Income

-$89.99M

EBITDA

-$74.62M

Operating Cash Flow

-$80.05M

Capital Expenditure

-$318.00K

Free Cash Flow

-$80.36M

Cash & ST Invst.

$211.46M

Total Debt

$9.11M

Evommune Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$349.00K

-113.3%

Gross Margin

0.00%

N/A

Market Cap

$431.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.00M

N/A

Employees

48

N/A

Net Income

-$21.67M

-48.9%

EBITDA

-$21.33M

-50.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$211.46M

+336.8%

Total Debt

$9.11M

-95.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.30M

-96.2%

Short Term Debt

$1.82M

+143.9%

Return on Assets

-23.57%

N/A

Return on Invested Capital

-28.86%

N/A

Free Cash Flow

-$27.59M

-15.4%

Operating Cash Flow

-$27.50M

-15.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OABIOmniAb, Inc.
$2.14+1.42%
ARTVArtiva Biotherapeutics, Inc.
$9.35+4.70%
KPTIKaryopharm Therapeutics Inc.
$10.01-0.40%
CDXSCodexis, Inc.
$2.13-5.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.63-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$75.02+0.03%
SPCXSpace Exploration Technologies
$136.08-0.02%
BMNRBitmine Immersion Technologies
$16.29+0.11%

Questions About EVMN

What is the current price of Evommune?

Evommune is trading at $11.99 per share.

What is the 52-week range for Evommune?

Over the past 52 weeks, Evommune has traded between $11.94 and $33.20.

How much debt does Evommune have?

As of the most recent reporting period, Evommune reported total debt of $9.11M.

How much cash does Evommune have on hand?

Evommune reported $48.32M in cash and cash equivalents in its most recent financial results.

What is Evommune’s dividend yield?

Evommune does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.